

PRIOR AUTHORIZATION REQUEST FORM EOC ID:

Cuvitru, HyQvia, and Hizentra

Phone: 800-728-7947 Fax back to: 866-880-4532

The Scott & White Health Plan Pharmacy Department manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. **Please note any information left blank or illegible may delay the review process.**

	Prescriber Name:		
Patient Name:	Supervising Physician:		
Member/Subscriber Number:	Fax:	Phone:	
Date of Birth:	Office Contact:		
Group Number:	NPI:	State Lic ID:	
Address:	Address:		
City, State ZIP:	City, State ZIP:		
Primary Phone:	Specialty/facility name (if a	pplicable):	
Drug Name and Strength:			
Directions / SIG:			
Please attach any pertinent medical history or information for this patient that may support approval. Please answer the following questions and sign.			
Q1. Is the patient a new start to therapy?			
Yes	□No		
Q2. For what diagnosis is this being prescribed?			
Q3. Please provide the ICD diagnosis code for the above condition.			
Q4. Is member meeting Medical Policy coverage? (Immune Globulin Therapy Policy can be found at https://swhp.org/en-us/prov/resources/policies).			
☐ Yes	□No		
Q5. Does the member have failure of an adequate trial of or clinically significant reaction to any of the following IV products? (Please select all that apply)			
☐ Bivigam	☐ Gammaked		
☐ Carimune	☐ Gammaplex		
☐ Flebogamma Dif	☐ Gamunex-C		
☐ Gamastan S/D	☐ Octagam		



PRIOR AUTHORIZATION REQUEST FORM EOC ID: Cuvitru, HyQvia, and Hizentra

Phone: 800-728-7947 Fax back to: 866-880-4532

The Scott & White Health Plan Pharmacy Department manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. **Please note any information left blank or illegible may delay the review process.**

Patient Name:	Prescriber Name: Supervising Physician:
☐ Gammagard Liquid ☐ Gammagard S/D	☐ Privigen ☐ None
Q6. Does the member have failure of an adequate trial of opposition products given subcutaneously? (Please select all that apposition in Gammagard Liquid in Gammaked in Gamunex-C in None	
Q7. Who is the ENTITY that will be submitting the CLAIM f Pharmacy Individual prescriber Provider or specialty group Facility Other (please specify) Q8. Provide name and NPI of the billing entity	or the DRUG and seeking reimbursement?
Q9. Will the claim for the drug be submitted as a MEDICAl submitting a MEDICAL claim for drug reimbursement, answ	
☐ Medical	☐ Pharmacy
Q10. Additional Comments:	
Prescriber Signature	Date



PRIOR AUTHORIZATION REQUEST FORM EOC ID: Cuvitru, HyQvia, and Hizentra

Phone: 800-728-7947 Fax back to: 866-880-4532

The Scott & White Health Plan Pharmacy Department manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. **Please note any information left blank or illegible may delay the review process.**

Prescriber Name:		
Patient Name:	Supervising Physician:	
□ Expedited/Urgent - By checking this box and signing abov	e. I certify that applying the standard review timeframe may	

 Expedited/Urgent - By checking this box and signing above, I certify that applying the standard review timeframe may seriously jeopardize the life or health of the enrollee or the enrollee's ability to regain maximum function

Lack of the necessary documentation may result in a medical necessity denial. Requesting providers may speak to a SWHP pharmacist or medical director at 1-800-728-7947 regarding the case to have an opportunity to help impact the decision on a request before coverage has been decided.

This telecopy transmission contains confidential information belonging to the sender that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action taken in reference to the contents of this document is strictly prohibited. If you have received this telecopy in error, please notify the sender immediately to arrange for the return of this document